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doi:10.1016/j.ejvs.2009.12.011Abstract Traditionally, stroke risk stratification has centred on the degree of internal carotid
artery stenosis, and the presence of focal neurological symptoms. However, degree of stenosis
alone is a relatively poor predictor of future stroke in asymptomatic patients; the Asymptom-
atic Carotid Surgery Trial highlighting the need to identify a subgroup of asymptomatics that
may benefit from intervention. Attempting to define this subgroup has inspired imaging
research to identify, in vivo, high-risk plaques. In addition to pre-operative risk stratification
of carotid stenosis, contrast enhanced ultrasound (CEUS) may be employed in monitoring
response to plaque-stabilising therapies.
Unlike most contrast agents used for computed tomography and magnetic resonance
imaging, microbubbles used in CEUS remain within the vascular space and can hence be used
to study the vasculature. In addition to improving current carotid structural scans, CEUS has
potential to add extra information on plaque characteristics. Furthermore, by targeting micro-
bubbles to specific ligands expressed on vascular endothelium, CEUS may have the ability to
probe plaque biology.
This review describes the current carotid ultrasound examination and the need to improve
it, rationale for imaging neovascularisation, use of CEUS to image neovascularisation, micro-
bubbles in improving the structural imaging of plaque, potential problems with CEUS, and
future directions.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.)7985 242 788; fax: þ44 (0)20 8846 7362.
ial.ac.uk (J. Shalhoub).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
382 J. Shalhoub et al.Introduction
Microbubble-based contrast agents are injected intrave-
nously to enhance ultrasound scans, and are composed of
1e10 mm diameter albumin or lipid shells filled with air or
high molecular weight gas. Their small size allows them to
recirculate, whereas larger bubbles are retained in the
pulmonary circulation.
The discovery that gas filled bubbles can act as ultrasound
contrast agents was initially made because the density
change from blood to intrabubble gas causes reflection of
soundwaves, just as the density change from air to cliff-face
creates an audible ‘‘echo’’. However, modern ultrasonic
methods of distinguishing microbubble from native tissue
rely on the fact that ultrasound waves causemicrobubbles to
compress and expand, whereas tissue is virtually incom-
pressible.1 By fortunate coincidence, the resonance
frequency for microbubbles (the frequency at which
compression and expansion occursmost readily) is within the
range of frequencies used for clinical ultrasound. Sound
waves of very low energy, therefore, will return detectable
signal from microbubbles, provided the transmitted wave is
around themicrobubble resonance frequency. Native tissue,
however, will not respond to such low energy waves.
Unlike most contrast agents used for computed tomog-
raphy (CT) and magnetic resonance imaging (MRI), micro-
bubbles remain within the vascular space and are hence
well suited to study the vasculature. By improving visual-
isation of the lumen, contrast enhanced ultrasound (CEUS)
can improve current carotid structural scans. Furthermore,
CEUS may be able to add extra information on plaque
characteristics, such as neovascularisation, deemed to
elucidate plaque instability. In addition, manufacturing
microbubbles targeted to specific vascular endothelial
ligands, CEUS may have the ability to probe plaque biology.
The current carotid ultrasound examination
With the publication of the results of the European Carotid
Surgery Trial (ECST)2 and the North American Symptomatic
Carotid Endarterectomy Trial (NASCET),3 the importance of
accurate assessment of the degree of internal carotid
artery diameter reduction has been highlighted. There has
been extensive work undertaken in the generation of reli-
able and reproducible criteria for the calculation of
internal carotid artery stenosis using unenhanced duplex
ultrasonography. This is based on largely velocity criteria, is
standardised and been used in the creation of national and
international society consensus documents.4e8 Duplex
ultrasonography is likely to remain the first line imaging
modality in this context5; as such, much work has been
undertaken in its refinement.
The need to improve the current ultrasound
assessment
Traditionally, stroke risk stratification has revolved around
the degree of internal carotid artery luminal narrowing,
and the presence of recent focal neurological symptoms
pertaining to the ipsilateral cerebral hemisphere. However,it has become apparent that the degree of stenosis alone is
a relatively poor predictor of future stroke in asymptomatic
patients. Indeed, the Asymptomatic Carotid Surgery Trial
(ACST)9 highlighted the need to identify a subgroup of
asymptomatics that would benefit from intervention.
The attempt to define this subgroup has inspired
research into imaging modalities which can identify, in
vivo, plaques at high risk of causing acute cardiovascular
events. Histological and functional techniques have deter-
mined the features of such plaques, including: inflamma-
tion; extra-cellular matrix degradation; neovascularisation;
intra-plaque haemorrhage; and apoptosis.10e12
Imaging techniques to identify these biological features
of the plaque in vivo could improve risk stratification,
facilitating clinicians’ treatment decisions and monitoring
response to plaque-stabilising therapies. To this end,
imaging intra-plaque inflammation, neovascularisation,
haemorrhage and apoptosis have been attempted with
some success using MRI and/or nuclear medicine. However,
high prevalence of carotid disease and expense associated
with these techniques preclude them from replacing
ultrasound as first line investigation.13e17
Using (non-contrast enhanced) ultrasound to identify
plaque constituents has been attempted with ‘‘Gray-Scale
Median’’ (GSM) evaluation. Studies in which patients were
imaged prior to surgical endarterectomy have consistently
demonstrated that plaques which are echolucent on ultra-
sound, with a low GSM, have high lipid, haemorrhage and
macrophage on histology. Conversely, echogenic plaques,
with a high GSM, have a higher fibrous content.18e21 GSM is
also associated with clinical findings: evidence of cerebral
infarction on CT is more common in the presence of echo-
lucent plaques rather than echogenic, regardless of symp-
tomatic status.22,23 Echogenicity on ultrasound has also
been shown to predict ipsilateral ischaemic stroke; patients
with echolucent plaques are at increased risk compared to
those with echorich plaques.24e26 However, hazard ratios
for development of stroke that are associated with differing
echogenicity scores are not sufficiently great to warrant
translation into clinical practice. Furthermore, studies
investigating the use of GSM in selection for carotid artery
stenting (CAS) have had conflicting results. The Imaging in
Carotid Angioplasty and Risk of Stroke (ICAROS) study
revealed that high echolucency increases risk of stroke as
a complication of CAS.27 Subsequently, Reiter and
colleagues showed no such relationship between plaque
echolucency and stroke risk with CAS.28Imaging neovascularisation: the rationale
Imaging intra-plaque neovascularisation may be a means by
which ultrasound can identify the high-risk plaque. In
healthy large vessels, the vasa vasorum runs through
adventitia and outer media,29 penetrating intima only in
pathology.30 Recent work has afforded a central role to
intra-plaque neovascularisation in initiation, progression
and rupture of atherosclerotic plaques.12,31e38 In animal
models, progression of disease can be reduced if neo-
vascularisation is inhibited with angiostatin,39 and growth
enhanced by administration of Vascular Endothelial Growth
Factor (VEGF).40
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angiogenic activity were originally noted in the late
1980s.41 Subsequently it was found that plaques bearing
hallmarks of vulnerability, including inflammation, hae-
morrhage, lipid accumulation and thin fibrous caps, are also
associated with increasing neovascularisation.37,38,42 Neo-
vascularisation appears to be an early feature of athero-
sclerosis, predating macrophage infiltration,36 and as the
plaque progresses so too does intimal neovascularisation.35
The majority of studies show carotid plaques retrieved at
endarterectomy have many more microvessels and tran-
scripts known to promote neovascularisation when they
originate from symptomatic, compared to asymptomatic
patients.42e45 Furthermore, symptomatic plaques have
been shown to contain abnormal, immature vessels that
may precipitate plaque instability through their acting as
sites of vascular leakage and so inflammation.42,44,46
Contrast enhanced ultrasound to image
neovascularisation
Limiting the success of MRI in imaging plaque neo-
vascularisation is the ceiling on imaging timepoints and the
fact that the contrast agent leaks from the vascular space.
CEUS does not suffer from these limitations and allows
quantification of vessels measuring less than 100 mm in
diameter.47 Unlike CT or MRI contrast agents, microbubbles
remain within the vasculature and act as ‘‘surrogate red
blood cells’’; hence they are true intravascular tracers
which can be imaged in real time.48 Combined with high
temporal and spatial resolution of ultrasound, CEUS is well
placed to study neovascularisation (Fig. 1).
Hitherto, three groups have correlated CEUS imaging
results with histological plaque neovascularisation. Fein-
stein reported a moderate correlation value of 0.6449; Coli
reported an increase in neovascularisation in patients
demonstrating extensive enhancement50; Giannoni et al.
reported diffuse contrast uptake in plaques from symp-
tomatic patients,51 all of whom had increased number of
microvessels confirmed on histology. The latter groupFigure 1 Contrast enhanced ultrasound of carotid intra-
plaque neovascularisation in longitudinal section, the micro-
bubbles are seen both within the internal carotid artery lumen
and within the carotid artheromatous plaque (green arrows).
Furthermore, there is a region of plaque which is not perfused
by microbubble contrast (white arrow).described the common presence of small vessels within
plaque underlying ulcerations.52 Up until this point, these
three groups used subjective visual assessment made by
human readers to ascribe binary or discreet scores to the
imaging findingsequantification can be improved by
generating time-signal intensity curves (Fig. 2) and using
automated image analysis to produce a continuous vari-
able. This approach has been demonstrated by Xiong and
colleagues who studied 104 carotid stenoses, revealing that
plaque enhanced intensity and the intensity normalised
against carotid luminal intensity were both significantly
greater in symptomatic versus asymptomatic atheromata.53
An alternative approach is to investigate periadventitial,
rather than intra-plaque, vasa vasorum. A recent study
compared quantified B-flow imaging (BFI) CEUS of peri-
adventitial vasa vasorum in patients with atherosclerotic
carotid stenosis compared with control carotids, showing
a significant difference as well as a correlation of BFI with
intima-media thickness (IMT).54
Future work will have to address current unanswered
questions about how best to quantify microbubble signal,
particularly how normalisation can account for administered
contrast dose and pharmacokinetic factors. Acquisition
techniques and methods of image analysis need to be
standardised, including in motion correction. Work with flow
phantoms may help with these issues. Validation of the
technique against a standardised clinical score, such as the
modified Rankin,55,56 Barthel57 or Frenchay,58 is required.
Alternatively, comparison with a standardised plaque histo-
logical score can be undertaken, such as that produced by the
American Heart Association in 1995,59,60 or a modification.61Microbubbles to improve structural imaging
of plaque
Further to potentially providing information on neo-
vascularisation as a biological feature of the atheroscle-
rotic plaque, CEUS has been shown to increase accuracy,
sensitivity and specificity of the structural disease assess-
ment.62 The concept of ‘‘Doppler-rescue’’ has emerged,
whereby contrast is introduced during an US examination at
the point of failure to obtain diagnostic images with
unenhanced scanning. It should be stated that in experi-
enced hands, ‘‘Doppler-rescue’’ is rarely required and this,
generally, would indicate the need for alternative imaging.
This should also be considered against the recent advances
in imaging technology. Furthermore, CEUS has been shown
to be of use in the depiction of unsuspected wall irregu-
larities, ulceration, and dissection,63 as well as improve the
resolution of IMT.64Potential problems with contrast enhanced
ultrasound
A small number of microbubbles will be destroyed by the
incoming ultrasound wave, and when this occurs capillary
damage may ensue. This in turn recruits vascular endo-
thelial growth factor (VEGF)-producing inflammatory cells,
stimulating neovascularisation.65 This phenomenon may be
a deterrent in the use of CEUS in diagnostics due to the
Figure 2 Quantification in contrast enhanced ultrasound A screenshot of the process of quantification in contrast enhanced
ultrasound using QLAB software (Philips Healthcare, Bothell, WA). A. Contrast mode is displayed. In this mode, in longitudinal
section, the contrast is seen clearly and the anatomy is seen less well. A region of interest (ROI) is drawn over the plaque (green). B.
B-mode ultrasound is displayed. This allows the anatomy to be visualised. The ROI (green) is automatically duplicated onto this
image. C. The process is repeated over all the acquired frames from the point of contrast injection to 2 min post-injection. D. Time-
intensity curve. This plots the intensity of contrast within the plaque, as identified by the green ROI, for each acquired frame. The
vertical white line identifies the point plotted for the images shown in A and B. The time-intensity curve can be modelled with
curve fitting functions. Quantifying contrast within the arterial lumen in the same way allows for normalisation. Of note, the
acquisition sequences required for visualising microbubbles produce intentionally weak signal from unenhanced areas of tissue.
Hence the parts of the plaque which are not perfused by microbubbles will appear echolucent regardless of these areas’ echo-
lucency on conventional B-mode ultrasound.
384 J. Shalhoub et al.theoretical risk of potentiating plaque instability by
promoting angiogenesis. However, at the low energies
employed for CEUS, very few microbubbles will be affected
and this is therefore a theoretical risk.
The undesirable effects that have been associated with
SonoVue, the most commonly used microbubble in the UK,
were in general, non-serious, transient and resolved spon-
taneously without residual effects. In clinical trials, the
most frequently reported adverse reactions were headache
(2.3%), injection site pain (1.4%), and injection site bruising,
burning and paraesthesia (1.7%).66 Fatal adverse events
(AEs) have occurred following the administration of micro-
bubbles. In the case of SonoVue, approximately 160,000
doses have been administered and 3 deaths have been
temporally related, although causal relationship was
uncertain. This fatal AE rate is an order of magnitude higher
than for MRI and CT contrast agents, probably reflecting the
comorbidities of the recipients (microbubbles are commonly
used in high-risk patients for echocardiography).67It is important to consider the cost related to the use of
ultrasound contrast agents. Although no formal health
economic assessment has been undertaken for the use of
microbubbles in carotid arterial disease, the technique has
been described as being cost-effective in the context of
gastrointestinal imaging.68
Future directions for contrast enhanced
ultrasound
Current microbubbles are used as blood pool agents
because, for all intents and purposes, they remain in the
vascular space. However, over time they have been shown
to be passively taken up by macrophages, such as Kupffer
cells in the liver, with the rate of phagocytosis being
a function of their shell’s constituents.69 Conjugation of
microbubbles with ligands creates the possibility of actively
targeting to specific molecules accessible from the vascular
Contrast Enhanced Ultrasound in Carotid Disease 385space. Kaufmann et al. have quantified vascular inflam-
matory changes occurring at different stages of murine
atherosclerosis utilising microbubbles targeted to vascular
cell adhesion molecule-1 (VCAM-1).70 Similarly, micro-
bubbles have been surface conjugated with the disintegrin
echistatin which binds to aV- and a5b1-integrins expressed
by the endothelium of neovessels.71 These tailored micro-
bubbles have been used to assess endogenous and fibroblast
growth factor-2-induced therapeutic neovascularisation in
a rodent model of hindlimb ischaemia. Such molecular
imaging with targeted microbubbles offers the possibility of
early pharmacodynamic readouts for drugs in development,
assisting drug discovery in the field of vascular
inflammation.
The carotid plaque has been imaged in 3-dimensions (3D)
with unenhanced ultrasound.72,73 The development of
contrast modes on high frequency 3D transducers offers the
opportunity to image carotid plaques in their entirety
during a single microbubble acquisition. This potentially
addresses two issues: out of plane motion for which there is
no solution in 2-dimensional (2D) CEUS bar the exclusion of
affected frames; and the false assumption that the single
slice imaged by 2D CEUS is representative of the entire
inhomogeneous plaque. As it is practically impossible to
select the same plaque slice for imaging over two sessions
using 2D CEUS, 3D imaging should improve reproducibility
and monitoring of therapy.
In addition to imaging, microbubbles may have a future
role in enhancing selectivity for delivery of therapeutics.
Ultrasound itself can improve uptake of drugs by causing
cavitation in the local cell membrane or increasing capillary
permeability, but the energy levels required to do so
exceed safety limits.74 However, by using ultrasound to
destroy microbubbles (ultrasound targeted microbubble
destruction (UTMD)) the amount of energy required to
create these local pores is reduced to within acceptable
limits. Moreover, if microbubbles are loaded with a drug of
interest, either on their surface or within the shell, UTMD
can further improve the selectivity of the drug delivery
system.74e76Conclusion
The paradigm shift in our understanding of features of
carotid atherosclerotic plaque instability has changed the
focus of carotid imaging from assessing structure (i.e.
degree of luminal narrowing) to exploration of the plaque
biology. To this end, the advent of 2D CEUS presents the
possibility of imaging plaque microvasculature, a proven
hallmark of vulnerability.
The application of CEUS for carotid atherosclerosis
primarily lies in the pre-operative risk stratification of
patients with asymptomatic stenosis, and monitoring the
response to plaque-stabilising therapies. However, prior to
CEUS entering the clinical arena in this context, it is essential
that quantification techniques are refined and internation-
ally standardized, and that prospective studies are per-
formed to elucidate the natural history of the evolution and
involution of plaque microvasculature. This will include the
establishment of appropriate time intervals for follow-up
scanning, and the full health-economic assessment thereof.Conflict of Interest
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